earli
event
infect
human
rectal
tumor
cell
bovin
coronaviru
investig
colloid
goldmedi
immunoelectron
microscopi
analysi
effect
lysosomotrop
weak
base
viru
yield
electron
microscop
studi
reveal
site
fusion
viru
envelop
plasmalemma
fusion
event
along
intracellular
membran
observ
despit
extens
search
virionantibodycolloid
gold
complex
fact
endocytos
synchron
infect
cell
complex
appar
noninfecti
accumul
vacuol
resembl
secondari
lysosom
exposur
cell
ammonium
chlorid
methylamin
first
hour
infect
littl
inhibitori
effect
product
infecti
viru
chloroquin
treatment
inhibitori
effect
depend
rel
late
event
infecti
process
chloroquin
inhibitori
step
block
infect
viru
adsorb
cell
expos
buffer
ph
rang
find
indic
bcv
penetr
host
cell
direct
fusion
plasmalemma
requir
acid
intracellular
compart
infecti
entri
bovin
coronaviru
bcv
member
famili
coronavirida
envelop
rna
virus
bcv
isol
studi
detail
agglutin
erythrocyt
rodent
thu
belong
hemagglutin
coronavirus
uniqu
envelop
coronavirus
three
glycoprotein
peplom
consist
e
membran
glycoprotein
molecular
mass
kda
glycoprotein
molecular
mass
kda
cell
fusion
function
cleavag
kda
precursor
hemagglutinin
molecular
mass
kda
dimer
kda
acetylesteras
activ
associ
hemagglutinin
bcv
replic
absorpt
epitheli
cell
intestin
tract
neonat
calv
induc
seriou
enter
diseas
although
mani
featur
coronaviru
replic
cultur
cell
describ
earli
event
bcv
infect
remain
poorli
character
least
two
distinct
pathway
evid
oper
entri
envelop
virus
anim
cell
virus
penetr
cell
direct
fusion
viral
envelop
plasma
membran
paramyxovirus
exampl
fuse
directli
cellular
plasma
membran
physiolog
condit
virus
fuse
plasma
membran
nonphysiolog
low
ph
level
second
pathway
envelop
viru
entri
involv
cellular
uptak
endocytosi
endocytos
virion
travel
membran
bound
intracellular
compart
acid
condit
maintain
low
ph
cellular
compart
appar
facilit
fusion
viral
envelop
vesicl
membran
result
releas
nucleocapsid
cytoplasm
infect
cultur
cell
varieti
envelop
virus
block
lysosomotrop
weak
base
base
accumul
cell
alter
ph
acid
cellular
compart
chang
appar
prevent
low
phdepend
viral
envelop
fusion
vesicl
membran
thu
block
infect
studi
inhibit
lysosomotrop
agent
indic
endocyt
mechan
entri
mous
coronaviru
valid
approach
recent
question
low
ph
condit
may
requir
bcv
entri
cell
infect
viru
fuse
slighli
basic
ph
condit
order
establish
rout
entri
bcv
examin
earli
event
infect
process
use
tysosomotrop
weak
base
colloid
gold
mediat
immunoelectron
microscopi
monolay
human
rectal
tumor
cell
line
grown
dulbecco
modif
eagl
medium
dmem
supplement
fetal
calf
serum
mebu
strain
bovin
coronaviru
propag
cell
viru
stock
prepar
cell
infect
multipl
approxim
pfu
per
cell
incub
day
serumfre
dmem
harvest
freezethaw
viral
titer
obtain
prepar
rang
pfu
per
ml
infect
titer
assay
monolay
grown
plate
monolay
adsorb
viru
h
overlay
serumfre
dmem
contain
agaros
itg
trypsin
difco
laboratori
detroit
mich
per
ml
day
incub
plaqu
count
without
stain
infect
cultur
harvest
post
infect
cell
evidenc
cytopath
chang
infect
materi
subject
two
freezethaw
cycl
disrupt
sonic
sonifi
branson
sonic
power
co
danburi
conn
sec
ice
releas
viru
viru
suspens
clarifi
centrifug
x
g
sediment
x
g
sucros
cushion
resuspend
dmem
ph
buffer
acid
hepe
mm
uptak
medium
recoveri
infecti
viru
rang
use
polyclon
rabbit
antibodi
bcv
particl
purifi
infect
bovin
fetal
kidney
cell
igg
fraction
obtain
proteina
sepharos
column
chromatographi
dilut
uptak
medium
level
produc
less
reduct
viru
infect
determin
plaqu
neutral
test
goat
antirabbit
antibodi
igg
complex
colloid
gold
particl
sp
suppli
west
chester
penn
use
probe
antibodi
bind
site
immunocytochem
investig
cell
monolay
grown
chamber
slide
rins
uptak
medium
chill
react
purifi
viru
min
multipl
pfu
per
cell
viruscel
complex
incub
ice
min
rabbit
antibcv
antibodi
wash
twice
uptak
medium
incub
rain
antibodycolloid
gold
probe
wash
cell
rapidli
warm
incub
variou
length
time
primari
fixat
glutaraldehyd
formaldehyd
sodium
cacodyl
buffer
ph
aldehydefix
monotay
postfix
h
solut
osmium
tetroxid
presenc
potassium
ferrocyanid
cacodyl
buffer
ph
dehydr
seri
alcohol
embed
situ
mixtur
epon
araldit
epoxi
resin
thin
section
stain
uranyl
magnesium
acet
lead
citrat
view
zeiss
electron
microscop
kv
monolay
cell
grown
plate
experi
involv
treatment
lysosomotrop
agent
yield
infecti
viru
determin
plaqu
assay
h
infect
infect
cell
synchron
temperatur
shift
analyz
rel
effect
chloroquin
ammonium
chlorid
methylamin
amantadin
monolay
wash
medium
chill
adsorb
min
bcv
multipl
approxim
pfu
per
cell
rins
cold
uptak
medium
remov
unadsorb
viru
monolay
given
warm
medium
appropri
lysosomotrop
base
transfer
incub
control
monolay
exposur
base
delay
h
post
infect
effect
variou
concentr
ammonium
chlorid
chloroquin
viru
infect
test
monolay
wash
uptak
medium
pretreat
rain
base
dilut
uptak
medium
ceil
infect
bcv
min
multipl
approxim
pfu
per
cell
given
fresh
uptak
medium
contain
base
exposur
lysosomotrop
agent
delay
h
post
infect
control
monotay
time
depend
inhibit
gm
chloroquin
analyz
measur
effect
increas
delay
chloroquin
addit
monolay
synchron
infect
describ
except
chloroquin
first
ad
cultur
variou
time
rewarm
ph
depend
chloroquin
inhibit
determin
monolay
allow
bind
bcv
wash
cold
dmem
cell
warm
addit
dmem
buffer
hepe
mm
nmorpholino
ethanesulfon
acid
me
variou
pit
level
given
fresh
uptak
medium
gm
chloroquin
chloroquin
ad
h
post
infect
final
concentr
jam
monolay
monolay
fix
rain
formaldehyd
permeabil
min
aceton
incub
rabbit
antibcv
antibodi
react
goat
antirabbit
antibodi
conjug
fluorescein
isothiocyan
prepar
view
leitz
fluoresc
microscop
field
photograph
use
epifluoresc
phase
contrast
optic
percentag
fluoresc
cell
prepar
calcul
randomli
select
field
approxim
cell
stock
solut
prepar
daili
mm
imm
ammonium
chlorid
methylamin
sigma
chemic
co
st
loui
mo
salin
solut
adjust
neutral
ph
naoh
dilut
uptak
medium
thin
section
cell
adsorb
bcv
particl
immunolabel
reveal
coat
pit
format
ceas
leav
virion
cell
exterior
fig
virion
readili
identifi
associ
colloid
gold
particl
use
highli
dilut
antibcv
antibodi
label
virion
gold
particl
particl
separ
fiom
viral
envelop
averag
distanc
nm
viru
particl
usual
contain
electrondens
core
spheric
shape
diamet
rang
nm
virion
ellipsoid
profil
also
observ
viral
envelop
separ
plasma
membran
distanc
less
n
mani
case
fibrillar
connect
evid
plasma
e
b
r
n
e
attach
site
fig
inset
peplorn
structur
bcv
distinct
neg
stain
could
rare
distinguish
viru
particl
unevenli
distribut
among
cell
cell
individu
thin
section
free
viru
particl
associ
one
two
virion
cell
observ
mani
virion
along
apic
cell
surfac
singl
thin
section
distribut
infer
viru
particl
adsorb
subpopul
cell
monolay
viru
particl
intracellular
locat
morpholog
less
readili
distinguish
associ
gold
label
permit
identif
intracellular
bcv
particl
uptak
bcvcell
complex
incub
min
label
bcv
particl
evid
coat
vesicl
small
multiform
vesicl
smooth
membran
fig
coat
vesicl
circular
profil
diamet
wherea
smooth
membran
vesicl
typic
larger
greater
dimens
divers
shape
profil
membran
compart
contain
one
two
viru
particl
littl
empti
space
nonvir
content
min
incub
intracellular
virion
accumul
larger
vacuol
nm
across
fig
vacuol
contain
mani
label
viru
particl
appear
partial
degrad
larg
vacuol
also
contain
unlabel
vesicl
fibrillar
strand
amorph
materi
featur
secondari
lysosom
gold
particl
close
associ
viru
structur
separ
nearest
limit
cellular
membran
distanc
exceed
nm
associ
gold
particl
vesicl
membran
rare
seen
fig
rewarm
gold
particl
observ
plasma
membran
site
distant
adsorb
virion
appar
fusion
viru
envelop
plasma
membran
record
fig
fusion
goldlabel
virion
intracellular
membran
never
observ
cell
surfaceadsorb
viru
incub
normal
rabbit
igg
instead
antibcv
antibodi
label
gold
probe
fig
furthermor
gold
particl
observ
plasma
membran
site
absenc
viru
particl
viruscel
complex
immunolabel
fix
control
indic
immunoreag
specif
mark
bcv
antigen
cell
membran
compar
effect
base
synchron
infect
cell
treat
chloroquin
amantadin
ammonium
chlorid
methylamin
tabl
concentr
previous
found
effect
studi
viru
entri
treatment
given
base
continu
viru
harvest
viru
yield
reduc
extent
inhibitor
degre
reduct
inhibitor
depend
durat
treatment
period
measur
viru
yield
cultur
treat
time
infect
compar
valu
yield
cultur
first
expos
inhibitor
h
post
infect
latter
valu
provid
baselin
could
evalu
effect
inhibitor
first
hour
infect
viru
yield
suppress
approxim
mm
ammonium
chlorid
mm
methylamin
ad
h
post
infect
presenc
base
first
hour
infect
reduc
bcv
yield
amantadin
stronger
inhibitor
viru
yield
inhibitori
effect
also
seen
control
prepar
thu
chloroquin
suppress
bcv
replic
first
hour
infect
infect
cell
expos
chloroquin
time
synchron
infect
harvest
produc
much
viru
cultur
treat
chloroquin
h
post
infect
synchron
bcv
infect
monolay
expos
variou
dose
ammonium
chlorid
chloroquin
time
temperatur
shift
avoid
drug
effect
viru
adsorpt
stage
second
set
monolay
pretreat
drug
rain
infect
ensur
intravacuolar
ph
level
alter
effect
agent
similar
infect
protocol
ammonium
chlorid
reduc
yield
bcv
synchron
infect
cell
less
logunit
even
mm
level
fig
similar
unrespons
ammonium
chlorid
treatment
occur
infect
pretreat
ammonium
chlorid
decreas
bcv
level
produc
agent
ad
h
delay
fig
synchron
infect
strongli
inhibit
gm
chloroquin
fig
cell
pretreat
base
infect
also
produc
less
viru
increas
concentr
inhibitor
fig
exposur
chloroquin
gm
level
result
optim
reduct
viru
yield
concentr
drug
higher
gm
diminish
total
viru
yield
h
delay
treatment
level
obtain
pretreat
inhibitori
effect
gm
chloroquin
earli
stage
bcv
replic
therefor
examin
close
subsequ
experi
immunofluoresc
studi
reveal
chloroquin
treatment
affect
number
bcvinfect
cell
monolay
tabl
treatment
synchron
infect
cultur
decreas
number
fluoresc
antigen
produc
cell
post
infect
replic
bcv
occur
cell
popul
untreat
cultur
less
cell
popul
produc
bcv
antigen
expos
chloroquin
time
infect
number
fluoresc
cell
monolay
reach
nearli
normal
level
treatment
delay
h
even
though
cell
vacuol
pronounc
fluoresc
cell
popul
express
percent
total
indic
time
post
infect
chloroquin
treatment
initi
variou
time
synchron
infect
fig
viru
yield
remain
low
level
cultur
initi
expos
drug
rain
less
exposur
chloroquin
delay
min
post
infect
viru
yield
suppress
inhibit
maximum
occur
treatment
delay
approxim
rain
result
show
rain
requir
infect
proceed
beyond
chloroquin
sensit
step
earli
stage
bcv
replic
electron
microscopi
reveal
bcv
particl
progress
endosom
lysosom
period
attempt
overcom
chloroquin
impos
block
bcv
entri
provid
condit
conduc
fusion
plasma
membran
envelop
infect
virion
monolay
viru
adsorb
expos
chloroquin
briefli
treat
warm
buffer
variou
ph
level
simul
condit
intracellular
vacuol
found
chloroquin
effect
inhibitor
bcv
infect
despit
buffer
treatment
ph
rang
fig
recent
investig
reexamin
role
endocytosi
infect
sever
anim
virus
morpholog
analys
gener
indic
coronavir
entri
accomplish
endocytosi
yet
investig
suggest
coronavirus
enter
cell
direct
fusion
plasma
membran
one
object
studi
employ
immunoloc
investig
entri
pathway
bcv
electron
microscop
analysi
reveal
fusion
viral
envelop
plasma
membran
confirm
bcv
particl
endocytos
cell
shortli
warm
viru
particl
seen
coat
pit
small
endocyt
vesicl
smooth
membran
viral
particl
accumul
later
structur
featur
secondari
lysosom
endocyt
event
resembl
superfici
altern
mode
infecti
entri
bcv
goldlabel
bcv
particl
mediat
highli
dilut
neutral
antibodi
reduc
infect
measur
extent
label
virion
probabl
repres
noninfecti
viru
antibodygold
complex
endocytosi
would
lead
sequestr
lysosom
compart
howev
event
appear
irrelev
infecti
entri
bcv
never
abl
find
clear
morpholog
evid
fusion
event
along
intracellular
membran
impli
bcv
effect
infecti
entri
direct
fusion
cell
surfac
experi
lysosomotrop
weak
base
conduct
assess
requir
acid
compart
bcv
infecti
entri
result
virtual
fail
reveal
unequivoc
involv
acid
compart
ammonium
chlorid
methylamin
rais
ph
endocyt
vesicl
inhibitori
event
first
hour
bcv
replic
endocytos
viral
particl
reach
lysosom
earli
infect
fusion
membran
observ
although
amantadin
treatment
time
infect
reduc
viru
yield
base
also
toxic
ad
delay
chloroquin
interf
rel
earli
stage
bcv
replic
determin
yield
infecti
viru
number
bcvinfect
cell
effect
appar
involv
inhibit
viral
envelop
fusion
cell
membran
besid
rais
ph
lysosom
chloroquin
exert
effect
cellular
function
includ
inhibit
viral
rna
synthesi
effect
may
respons
drop
bcv
product
drug
ad
h
rewarm
probe
chloroquin
sensit
earli
stage
bcv
infect
kinet
time
depend
chloroquin
inhibit
lead
us
conclud
sensit
step
bcv
replic
occur
min
infect
fig
addit
chloroquin
late
min
rewarm
inhibit
replic
substanti
contrast
infect
semliki
forest
viru
sfv
enter
cell
endocyt
pathway
reach
chloroquin
insensit
phase
within
later
treatment
base
rel
ineffect
brief
treatment
sfvadsorb
cell
cultur
low
ph
media
lift
chloroquin
block
appar
induc
viru
fusion
plasma
membran
chloroquineblock
step
bcv
infect
essenti
unaffect
ph
treatment
rang
failur
reliev
chloroquin
block
bcv
replic
would
expect
plasma
membran
fusion
bcv
trigger
low
ph
treatment
find
harmoni
bcvinduc
cell
fusion
infect
bovin
fetal
spleen
cell
fuse
optim
slightli
basic
ph
similar
murin
coronavirushost
cell
system
altern
explan
continu
chloroquin
block
despit
low
ph
treatment
inhibit
event
replic
subsequ
fusion
investig
sindbi
viru
infect
conclud
chloroquin
inhibit
postfus
event
replic
viru
inhibitori
activ
attribut
effect
viral
rna
synthesi
rather
block
sindbi
viru
entri
cell
data
indic
bcv
infect
involv
endocyt
rout
endocytosi
viru
appear
repres
abort
infect
subsequ
viru
degrad
lysosom
virion
endocytos
observ
fuse
vesicl
membran
instead
particl
accumul
somewhat
degrad
form
lysosomelik
structur
furthermor
low
ph
compart
appar
unnecessari
bcv
infect
virusinduc
membran
fusion
seem
event
independ
low
ph
treatment
featur
suggest
bcv
infect
cell
direct
fusion
plasma
membran
doughri
et
al
observ
interact
bcv
strain
plasmalemma
infect
intestin
epitheli
cell
assert
viru
uptak
occur
direct
fusion
plasma
membran
studi
provid
evid
support
conclus
note
ad
proof
recent
publish
report
describ
characterist
mous
coronaviru
spike
glycoprotein
consist
role
infectionpenetr
plasma
membran
rather
within
endocyt
vesicl
